The weight-loss drug revolution

John Laurenson reports from La Défense in Paris on how Europe's biggest business district is turning vacant office space into housing. As hybrid working leaves more offices underused, cities are rethinking the future of these buildings. We compare developments in Paris with effor ...  Show more

Headspace started life as a mindfulness app. Now it's partnering with the US Navy and investing in artificial intelligence for mental health support.The company's CEO Tom Pickett speaks to us about therapy, the increasing role of technology, and tackling burnout at scale.If you'd ...  Show more

Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ...  Show more

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ...  Show more

GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapid ...

You may have heard about Ozempic, Wegovy and Mounjaro. It’s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of ...  Show more